Active surveillance (AS) is the preferred strategy for favorable-risk prostate cancer, yet current protocols rely on scheduled repeat biopsies, most of which reveal no progression and are unnecessary. Existing risk-stratification tools operate on single time-point imaging or depend on explicit lesion segmentation, limiting their ability to capture longitudinal change and excluding patients without an MRI-visible lesion.
arXiv:2608.21497v1 Announce Type: cross
Abstract: Biochemical recurrence (BCR), defined as any detectable prostate-specific antigen level after prostatectomy with confirmatory elevation, is widely us...
By Robert N. Spaans, Catherine Chia, Tongjie Wang, Adam Kowalewski, Parandzem Khachatryan, Domingos Oliveira, Khrystyna Faryna, Jean-Paul A. van Basten, Geert Litjens, Nadieh Khalili
arXiv:2607. 06919v1 Announce Type: cross Abstract: Artificial intelligence (AI) analysis of micro-ultrasound ($\mu$US) has shown promise for prostate cancer (PCa) detection.
By Paul F. R. Wilson, Mohamed Harmanani, Zhuoxin Guo, Obed K. Dzikunu, Hannes Cash, Adam Kinnaird, Brian Wodlinger, Purang Abolmaesumi, Parvin Mousavi
arXiv:2606.28676v2 Announce Type: replace-cross
Abstract: Predicting distant metastasis from the digital H & E slides of the primary tumor is a critical yet challenging task in computational patholog...
By Sandesh Pokhrel, Hamid Manoochehri, Beatrice S Knudsen, Tolga Tasdizen
The paper introduces a modular framework for multimodal AI fusion that combines slide-level embeddings from histology images with per-visit clinical embeddings using 15 interchangeable fusion methods. Applied to a prospective cohort of newly diagnosed inflammatory bowel disease patients, the best fusion method achieved macro‑F1 scores between 0.57 and 0.75, outperforming single‑modality models in most scenarios and showing varying reliance on image data depending on the remission outcome. The study highlights how different fusion strategies can influence predictive performance across distinct clinical endpoints.
By Ankana Banerjee (University of Stavanger, Norway), Mark van der Giezen (University of Stavanger, Norway), Ole Gunnar Aasprong (Stavanger University Hospital, Norway), Emiel A. M. Janssen (University of Stavanger, Norway), {\O}yvind Steinsb{\o} (Stavanger University Hospital, Norway), Tore Grimstad (Stavanger University Hospital, Norway), Kjersti Engan (University of Stavanger, Norway)
arXiv:2510. 17529v3 Announce Type: replace-cross Abstract: Active Surveillance (AS) is a treatment option for managing low and intermediate-risk prostate cancer (PCa), aiming to avoid overtreatment while monitoring disease progression through serial MRI and clinical follow-up.
By Yovin Yahathugoda, Davide Prezzi, Patricia A. Gutierrez, Piyalitt Ittichaiwong, Vicky Goh, Sebastien Ourselin, Michela Antonelli